Durata Therapeutics has submitted an MAA to the EMA for dalbavancin, for the treatment of patients with complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positive microorganisms, including Staphylococcus aureus (including methicillin-resistant strains) and Streptococcus pyogenes, as well as certain other streptococcal species. Following the standard EMA review cycle timing, the company anticipates a decision in 1H15. If approved, dalbavancin will be the first drug f...